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Abstract
Background: Lower respiratory tract infections like acute bronchitis, exacerbated chronic
obstructive pulmonary disease and community-acquired pneumonia are often unnecessarily treated
with antibiotics, mainly because of physicians' difficulties to distinguish viral from bacterial cause and
to estimate disease-severity. The goal of this trial is to compare medical outcomes, use of
antibiotics and hospital resources in a strategy based on enforced evidence-based guidelines versus
procalcitonin guided antibiotic therapy in patients with lower respiratory tract infections.
Methods and design: We describe a prospective randomized controlled non-inferiority trial with
an open intervention. We aim to randomize over a fixed recruitment period of 18 months a
minimal number of 1002 patients from 6 hospitals in Switzerland. Patients must be >18 years of age
with a lower respiratory tract infections <28 days of duration. Patients with no informed consent,
not fluent in German, a previous hospital stay within 14 days, severe immunosuppression or
chronic infection, intravenous drug use or a terminal condition are excluded. Randomization to
either guidelines-enforced management or procalcitonin-guided antibiotic therapy is stratified by
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centre and type of lower respiratory tract infections. During hospitalization, all patients are
reassessed at days 3, 5, 7 and at the day of discharge. After 30 and 180 days, structured phone
interviews by blinded medical students are conducted. Depending on the randomization allocation,
initiation and discontinuation of antibiotics is encouraged or discouraged based on evidence-based
guidelines or procalcitonin cut off ranges, respectively. The primary endpoint is the risk of
combined disease-specific failure after 30 days. Secondary outcomes are antibiotic exposure, side
effects from antibiotics, rate and duration of hospitalization, time to clinical stability, disease activity
scores and cost effectiveness. The study hypothesis is that procalcitonin-guidance is non-inferior
(i.e., at worst a 7.5% higher combined failure rate) to the management with enforced guidelines,
but is associated with a reduced total antibiotic use and length of hospital stay.
Discussion: Use of and prolonged exposure to antibiotics in lower respiratory tract infections is
high. The proposed trial investigates whether procalcitonin-guidance may safely reduce antibiotic
consumption along with reductions in hospitalization costs and antibiotic resistance. It will
additionally generate insights for improved prognostic assessment of patients with lower
respiratory tract infections.
Trial registration: ISRCTN95122877
Background
Lower respiratory tract infections (LRTI) including acute
bronchitis, acute exacerbations of chronic obstructive pul-
monary disease (AECOPD) and community-acquired
pneumonia (CAP), account for almost 10% of the world-
wide burden of morbidity and mortality, and thus, impor-
tantly contribute to antibiotic overuse and allocation of
health resources [1,2]. Although most LRTI are of viral ori-
gin, approximately 75% of antibiotics are prescribed
because viral etiology and disease severity are difficult to
recognize with traditional clinical and laboratory means
[2]. Current criteria for assessing the severity of CAP, such
as the pneumonia severity index (PSI) and the CAP sever-
ity on presentation to hospital scale (CURB65) are well
validated, but have important drawbacks for routine care
[3-6]. They only predict mortality in CAP and depend
mainly on age, thereby underestimating the disease-
related morbidity in younger patients. Furthermore, they
dichotomize continuously measured values (e.g. respira-
tory rate) into normal and abnormal values and show a
high intra-observer variation of around 10 percent.
A widely used approach to estimate the probability of a
bacterial origin and the disease severity of a LRTI is the use
of the C-reactive protein. However, this biomarker lacks
sensitivity and specificity, and thorough studies about its
effect on antibiotic use are lacking [7,8]. More promising
appears to be the level of circulating procalcitonin (PCT)
which has been demonstrated to correlate with the likeli-
hood for a bacterial infection [7,9]. We conceived and suc-
cessfully validated PCT guided diagnosis using cut-off
ranges in the continuum of LRTI in four intervention trials
by randomizing patients to PCT guided antibiotic pre-
scription versus standard care and monitored clinical out-
come. In these trials we circumvented the gold standard
dilemma for the etiologic diagnosis of LRTIs by assuming
absence of serious bacterial infection in patients recover-
ing without antibiotics [10-14].
Some limitations of the previous intervention trials need
to be considered. Three of the four trials were conducted
at a single University Hospital, limiting the external valid-
ity of this approach [11,12,14]. Routine use of guidelines
for antibiotic prescriptions was only partly enforced in the
standard care group [11-14]. Only the primary care trial
had adequate power to show non-inferiority in days with
restrictions from LRTI by PCT guidance. However, the trial
was not designed to show non-inferiority from severe
infectious disease complications, more typically seen in
hospitalized patients with higher complication rates.
Finally, despite a marked reduction of the duration of
antibiotic therapy by PCT guidance, the length of hospital
stay was not reduced since it was not a target of interven-
tion in all previous trials.
The aim of the proposed "ProHOSP"-study is to address
these limitations from the previous trials and to study
additional diagnostic and prognostic biomarkers for the
management of LRTIs. In addition this trial shall assess
the impact of a biomarker driven LRTI management on
hospital stay and costs.
Methods
The objectives of this randomized controlled, open inter-
vention trial are to evaluate whether a PCT guided diag-
nostic and therapeutic strategy in patients with LRTI lead
to similar patient relevant outcomes, reduced total antibi-
otic use as well as length of hospitalization as compared
to a management without PCT testing but based on the
enforced implementation of current guidelines. The pri-BMC Health Services Research 2007, 7:102 http://www.biomedcentral.com/1472-6963/7/102
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mary study hypothesis is that a PCT guided LRTI manage-
ment is non-inferior to standard care based on
implemented guidelines. The primary endpoint is disease
specific failure within 30 days following index hospital
admission and we assume non-inferiority if the combined
disease specific failure rate is less than 7.5%.
Patients from six hospitals in Switzerland are being
included. Full ethical approval for this trial which is in
compliance with the Helsinki Declaration has been
obtained from all local ethical committees. All responsi-
ble heads of the medical departments of the participating
study hospitals have approved and signed the study pro-
tocol and all participating patients must give written
informed consent.
This trial is supervised by an independent safety monitor-
ing board which is not involved in the design and the con-
duct of the trial. The board consists of a pneumologist, an
infectious disease specialist and an intensive care special-
ist.
Setting
We recruit the patients in six secondary and tertiary care
clinics in northern and central Switzerland. The character-
isation of the study clinics is presented in table 1. The 6
public hospitals are variable in size, patient care capacity
and employment of medical and nursing staff, but have a
comparable length of hospital stay per patient (mean hos-
pital stay 8.3 +/- 0.57 days)[15].
Local investigators and their staff received a structured
seminar to become familiar with the details of the proto-
col, the rationale and the design of the trial, the study
website for patients inclusion and randomisation and all
study forms.
In December 2006, all participating hospitals started to
consecutively screen all adult patients admitted to the
emergency department with suspected LRTI.
Participants
Inclusion criteria for patients are written informed con-
sent, age ≥ 18 years and admittance from the community
or a nursing home with the main diagnosis of acute LRTI
(i.e., less than 28 days). LRTI is defined by at least one res-
piratory symptom (cough, sputum production, dyspnea,
tachypnea pleuritic pain) plus one auscultatory finding or
sign of infection (core body temperature >38.0°C, shivers,
leucocyte count >10 G/L or <4 G/L cells) independent of
antibiotic pre-treatment. The LRTI conditions are defined
as follows: CAP is defined as a new or increased infiltrate
on chest radiograph [16,17]. COPD is defined by post-
bronchodilator spirometric criteria according to the
GOLD-guidelines as a FEV1/FVC ratio below 70% and the
severity categorized according to GOLD criteria [18,19].
Acute bronchitis is defined as LRTI in the absence of an
underlying lung disease or focal chest signs or infiltrates
on chest X-ray, respectively [20]. Exclusion criteria are the
inability to give written informed consent, insufficient
German language skills, active intravenous drug users,
severe immunosuppression, accompanying chronic infec-
tion or endocarditis or very severe medical co-morbidity
where death is imminent.
Intervention
Clinicians in the emergency departments of participating
clinics are advised to access a web based study algorithm
and enter baseline data of all eligible patients with LRTI
on admission and to check all inclusion and exclusion cri-
teria prior to randomisation (figure 1). Randomization of
patients to PCT guidance or guideline enforced antibiotic
therapy is based on a pre-specified computer generated
randomization list and concealed by using a centralized
password-secured website [21]. This website provides all
study-related information including guidelines and
Table 1: Baseline characteristics of the six participating study hospitals in the northern and central part of Switzerland [15].
Baseline characteristics of the study hospitals
Universitäts-
spital Basel
Kantonsspital 
Liestal
Kantonsspital 
Luzern
Kantonsspital 
Aarau
Bürgerspital 
Solothurn
Kantonsspital 
Münsterlingen
Status Public Public Public Public Public Public
Number of beds 694 371 616 539 254 252
Mean length of 
stay (days)
8.5 9.9 8.5 8.5 9.3 8.3
% of private 
medical coverage*
28.3 19.0 18.9 18.5 25.1 15
Medical staff** 849 125 414 376 97 350
Nursing staff** 1047 315 1074 979 417 414
*Average of medical and surgical patients
** All personal for the care of medical and surgical patientsBMC Health Services Research 2007, 7:102 http://www.biomedcentral.com/1472-6963/7/102
Page 4 of 9
(page number not for citation purposes)
patient flow. The randomization is stratified by the partic-
ipating clinic and the type of LRTI (acute bronchitis,
AECOPD, CAP).
We summarized guidelines on the management of CAP,
acute bronchitis and AECOPD based on the most recent
guidelines by the European Respiratory Society (ERS) and
the American Thoracic Society (ATS) supplemented by
evidence from recent guidelines and published current
concepts [16,17,19,20]. These guidelines have been
adapted by a panel of local internists, emergency physi-
cians, pneumologists, infectious disease experts and clini-
cal epidemiologists and have been successfully used in the
clinical setting. To optimize the implementation of these
guidelines for all patients the treating physician is
enforced to follow web-based guideline algorithms, con-
trolled by email alerts released for every patient screened
and recruited, respectively. If the algorithm for PCT guid-
ance or the guidelines for antibiotic therapy are overruled,
the study centre has to be informed as soon as possible.
PCT is measured using a rapid sensitive immunoassay
with a functional assay sensitivity of 0.06 ug/L (Kryptor
PCT, Brahms, Hennigsdorf, Germany). The coefficient of
variation of the assay at 0.1 ug/L, 0.25 ug/L, 0.5 ug/L and
10 ug/L were 16%, 7%, 5% and 3%, respectively. The test
is performed at the central lab of each participating hospi-
tal. The assay time for PCT measurements require less
than 20 minutes and PCT results are routinely available
within one hour upon ordering.
PCT levels are communicated by the password secured
website to the treating physician together with a treatment
recommendation for antibiotics based on the PCT algo-
rithm exclusively for patients randomized to the PCT
intervention arm. Similarly, for the patients in the guide-
line-enforced group treatment recommendation based on
All consecutive patients with lower respiratory tract infection are potentially eligible for this trial Figure 1
All consecutive patients with lower respiratory tract infection are potentially eligible for this trial. If all inclusion criteria are ful-
filled and no exclusion criteria are present, the physician has to explain to the patient the trial, ask for participation and get 
informed consent. After inclusion, the patient is randomized by a web based computerized random allocation algorithm to 
either the guidelines group or the PCT group, respectively. CAP denotes community-acquired pneumonia, AECOPD acute exac-
erbation of chronic pulmonary disease, AB antibiotics, PCT procalcitonin.BMC Health Services Research 2007, 7:102 http://www.biomedcentral.com/1472-6963/7/102
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guidelines are displayed. All participating physicians
received detailed information about the use of PCT cut off
ranges and the algorithm as presented in figure 2 is pub-
lished in the investigators brochure and on the internet
platform.
In both groups, hospitalized patients are clinically reas-
sessed and blood is sampled on days 3, 5, 7, and on the
day of discharge to assess the resolution of the presumed
infection. In both groups, a switch of antibiotics from
intravenous to oral is advised if patients show stable or
improving vital signs, resolution of the predominant clin-
ical sign or if oral intake is possible (adequate conscious-
ness and reflexes to swallow fluids and tablets, no
malabsorption) [16,17]. In hospitalized patients with an
acute bronchitis, a chest X-ray after 3–5 days is routinely
performed to confirm the diagnosis and exclude pneumo-
nia.
In all hospitalized patients hospital discharge should be
considered if oral intake is feasible, vital signs are stable >
24 h (as defined above), and no evidence of acute serious
co-morbidity that necessitates hospitalization is present
and, if the patient has achieved pre-admission mobility
state [16,17]. At the day of discharge, all patients receive 2
leaflets providing general information for the patient and
the general physician (GP) regarding this trial.
Outcomes and adverse events
The primary endpoint of this trial is the combined dis-
ease-specific failure rate within 30 days. The following
events are considered as failures: (a) radiologically, micro-
biologically or clinically confirmed recurrence of infec-
tion in need of antibiotics, (b) local or systemic
complications from LRTI including persistence or devel-
opment of pneumonia (including nosocomial), parap-
neumonic effusions, lung abscess, empyema, any abscess
(pharyngeal, parapharyngeal, sinusitis requiring sinus
drainage, any remote abscess), acute respiratory distress
syndrome (ARDS), (c) admission to the intensive care
unit (ICU), (d) disease related hospital readmission and
(e) death from any cause.
The secondary endpoints of this trial are (a) antibiotic
exposure for LRTIs (antibiotic prescription times duration
of antibiotic therapy), (b) side-effects from antibiotic
treatment, (c) time to clinical stability, (d) length of hos-
pital stay and (e) quality of life according to EuroQol and
LRTI-specific disease activity score[22]. Five projects per-
formed alongside to this trial (cost-effectiveness of PCT
guided antibiotic therapy, impact of nursing and social
factors for rate and duration of hospitalization, other
biomarkers as diagnostic and prognostic tools in LRTI,
free cortisol and copeptin levels to assess disease-related
stress, microcalorimetry as a novel method for rapid diag-
nosis of bloodstream infections) synergize scientific
efforts.
Outcomes are assessed during hospital stay at days 3, 5
and 7, and at hospital discharge and by structured phone
interviews at days 30 and 180 (figure 1) by medical stu-
dents blinded to the treatment allocation of the patients.
In case the patient is indicating the prescription of any
new antibiotic or any unnamed drug following hospital
discharge or is unable to give adequate information, or
has been rehospitalised, the interviewer is obliged to con-
tact the treating GP or the hospital and to receive notifica-
tion of the prescription or a copy of the hospital
transferral or demission letter.
Antibiotic stewardship based on procalcitonin (PCT) cut-off  ranges Figure 2
Antibiotic stewardship based on procalcitonin (PCT) cut-off 
ranges. Re-evaluation of the clinical status and measurement 
of serum PCT levels is mandatory after 6–24 h in all persist-
ently sick and hospitalized patients in who antibiotic are with-
held. The PCT algorithm can be overruled by pre-specified 
criteria, e.g. in patients with immediately life-threatening dis-
ease. If the algorithm is overruled and antibiotics are given, 
an early discontinuation of antibiotic therapy after 3, 5 or 7 
days is more or less endorsed based on PCT levels. In hospi-
talized patients with ongoing antibiotic therapy PCT levels 
are reassessed on days 3, 5 and 7 and antibiotics will be dis-
continued using the PCT cut-offs defined above. In all 
patients with a very high PCT value on admission (e.g., >10 
µg/L), discontinuation of antibiotic is already encouraged if 
levels decreased below 80 to 90% of the initial value. In 
patients discharged and, thus, likely uncomplicated resolution 
of the infection or in patients transferred to an institution 
not taking part in this trial the recommended total duration 
of antibiotic therapy is based on the last PCT level and is as 
following: >1 ug/L 7 days, 0.5–0.99 ug/L 5 days, 0.25–0.49 ug/
L 3 days, <0.25 ug/L stop antibiotic, <0.1 ug/L STOP antibi-
otic. PCT denotes procalcitonin, AB antibiotics,Tbc tuberculo-
sis, ICU intensive care unit,BMC Health Services Research 2007, 7:102 http://www.biomedcentral.com/1472-6963/7/102
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Endpoints are reassessed by an independent endpoint
committee of at least 2 clinicians blinded to patient allo-
cation. Endpoint judgment is based on the case report
form and, if necessary, on hard copies of the hospital chart
that are made anonymous and blinded in regard to any
information on PCT. In order to truly blind endpoint
assessors all information on PCT will be discarded on rel-
evant documents.
An adverse event in a subject is defined as any occurrence
of unfavourable and unintended clinically relevant medi-
cal sign, symptom, or disease temporally associated with
the study which does not necessarily have a causal rela-
tionship with the study procedure. If an adverse event
occurs, the responsible clinician involved in the case is
contacted by an unblinded member of the study team to
verify all information and to complete a serious adverse
event form. All adverse events within 180 days after study
inclusion are monitored and continuously evaluated by
the data safety and monitoring board. All adverse events
must be followed until resolution, until the condition sta-
bilizes, until the event is otherwise explained, or the sub-
ject is lost to follow-up or has died.
Sample size and statistical considerations
The goal of this ongoing trial is to show non-inferiority of
the PCT guided antibiotic management approach in com-
parison to enforced guidelines for the primary endpoint
(i.e. the disease-specific failure rate within 30 days). To
estimate the frequency of the primary endpoint, we used
the data from our previous intervention trials [11,12,14].
Based on these data, the risk of disease-specific failure in
evaluable patients is assumed to be around 15% and, if
losses to follow-up are treated as failures, the failure rate
of all patients may increase to 20%. We assume non-infe-
riority if the disease specific failure for patients on procal-
citonin-guided antibiotic therapy is less than 7.5% higher
compared to those on guidelines-enforced management.
Based on these estimates and assumptions, a minimal
number of 1002 patients (501 patients per arm) are
required. Table 2 displays the power calculations for dif-
ferent assumed failure differences and non-inferiority
boundaries with a one-sided type I error of 5% and a
power of 80% to 90%. With 1002 patients, we have 80%
power to exclude differences in failure rates of more than
9–12% in the respective LRTI subgroups and of ≥6% in
death rates. In practice, a fixed recruitment period of 18
months is considered and all patients recruited in that
period be randomized unless sample size after 18 months
is below 1002 patients, which would lead to an extension
of the recruitment period. The target size at each centre is
250 patients completed per protocol.
The primary analysis population is the full analysis set
which includes all randomized patients following an
intention-to-treat principle. For the primary analysis,
losses to follow-up (on both arms) are regarded as treat-
ment failures. A (two-sided) 90% confidence interval for
the difference of the disease-specific failure rates will be
calculated based on Cochran's test stratified by type of
LRTI. If the confidence interval for the difference excludes
7.5% or more, the primary objective will be met. As a sen-
sitivity analysis, the primary analysis will be repeated on
the subset of patients with evaluable outcome only, i.e.
drop-outs are excluded from this additional analysis, as
well as the per-protocol population which excludes non-
evaluable cases and major protocol violators.
In a second step, the primary endpoint will be explored
for association with potential prognostic factors in a logis-
tic regression. The factors that will be considered are: age,
sex, LRTI subgroup, PSI and CURB65 score in CAP
patients and GOLD criteria and Anthonisen type of exac-
erbation in COPD patients [18,23]. Potential centre
effects will be tested by including centre and physician as
a random effect.
The trial data and sample base will be used for several pre-
specified additional analyses. Theses projects include the
development of clinical prediction rules for adverse med-
ical outcomes in community-acquired LRTIs and to com-
pare the diagnostic and prognostic accuracy of promising
new biomarkers (e.g. proadrenomedullin (proADM), pro
atrial natriuretic peptide (MR-proANP), copeptin, total
and free cortisol) with traditional clinical signs and symp-
toms, the PSI and the CURB-65 score for patients with
CAP and the Anthonisen criteria for patients with
AECOPD [3,6,18,24-29].
Discussion
This ongoing multicenter trial is the first prospective, ran-
domized controlled trial in hospitalized patients with
LRTI sufficiently powered to show non-inferiority of a
PCT guided antibiotic management compared to enforced
guidelines. This trial has the potential to demonstrate
Table 2: Required total sample size
True assumed failure 
rate in both arms
Required total sample size
∆ = 5%
Power 90% 
(80%)
∆ = 7.5%
Power 90% 
(80%)
∆ = 10%
Power 90% 
(80%)
10% 1278 (932) 578 (426) 330 (244)
15% 1792 (1302) 806 (588) 458 (334)
20% 2232 (1624) 1002 (730) 570 (418)
Sample size calculation for the primary endpoint, i.e. required sample 
size to conclude at the one-sided 5%-level that the disease-specific 
failure rate in PCT-guided arm is at most ∆ higher compared to 
management with enforced guidelines with a power of 80–90%.BMC Health Services Research 2007, 7:102 http://www.biomedcentral.com/1472-6963/7/102
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whether antibiotic stewardship based on PCT cut-off val-
ues reduces antibiotic exposure without compromising
patient relevant outcomes. The present protocol should
allow a more wide-spread implementation of the pro-
posed PCT algorithm for further external validation with
the aim to optimise the management of LRTIs by avoiding
unnecessary antibiotic use, costs and side effects from
antibiotics.
Notwithstanding the impact of PCT to improve diagnosis
and antibiotic use in LRTI, its prognostic value on admis-
sion to predict complications from LRTI is limited. Other
biomarkers may have better potential in the prognostic
assessment of LRTIs and sepsis on admission. For exam-
ple, adrenomedullin is one of the most potent vasodilat-
ing agents with immune modulating, metabolic and
bactericidal properties [30,31]. Adrenomedullin precur-
sor levels are elevated in sepsis and CAP, have a similar
accuracy to predict death compared to the APACHE II
score in critically ill patients and also improve the prog-
nostic accuracy of the PSI in CAP, providing an additional
margin of safety [28,29]. Another candidate biomarker is
the atrial natriuretic peptide (ANP), a member of the fam-
ily of natriuretic peptides that regulates a variety of physi-
ological parameters [32]. In CAP, the level of ANP
precursor peptides (MR-proANP) may mirror both, the
inflammatory cytokine response correlated with the sever-
ity of pneumonia, as well as the presence of disease-rele-
vant comorbidities, namely heart failure and renal
dysfunction [33,34]. Plasma MR-proANP levels are
increased in LRTI with highest levels in CAP and are better
predictors of severity and outcome of CAP as compared to
commonly measured clinical and laboratory parameters
and comparable to the PSI [25,35]. Another promising
biomarker is copeptin, stoichiometrically converted to
vasopressin which has hemodynamic and osmoregula-
tory effects, and reflects the individual stress response
[36]. Copeptin levels increase with increasing severity of
CAP, as classified by the PSI score and in patients with
acute exacerbations of COPD copeptin was shown to be
predictive of long-term clinical failure independent of age,
co-morbidity, hypoxemia and lung functional impair-
ment in multivariate analysis [24,27,37]. The additional
prognostic value of these novel biomarkers in the careful
clinical assessment shall be validated within this trial for
a better estimate of the likelihood for adverse medical out-
comes.
Based on the large body of evidence generated by the Pro-
HOSP study, a further trial is planned. Thereby, we plan
to combine the structured clinical assessment with diag-
nostic and prognostic biomarkers including pivotal
aspects of nursing care and social factors to conceive and
implement pre-emptive early discharge measures. With
the integration and validation of these new biomarkers
and clinical assessment tools we expect a large potential to
safely optimize health care resources. Thereby, LRTI will
serve as "proof-of-concept" for other diseases.
Potential limitations
Obviously, a state-of-the-art microbiological evaluation is
necessary for decisions about appropriate step-down ther-
apy and the use of narrow-spectrum antibiotics. However,
we do not interfere with the choice of antibiotics. Rou-
tinely available methods to clarify the etiology of acute
respiratory tract infections have limitations. The diagnosis
of viral infection is cumbersome, expensive, delayed, and
is not needed for the primary endpoint. Influenza-testing
would require a cumbersome nasopharyngeal swab.
Based on our data using a sensitive assay serological evi-
dence of viral infection was found in almost 80% of
assessed cases [11,12]. This rate was independent of the
diagnostic subgroup of LRTI (acute bronchitis/AECOPD/
CAP). However, even a positive viral serology does not
rule out complicating bacterial infection. Conversely,
microbial cultures are of limited value. For example, CAP
is thought to be of predominantly bacterial origin.
Despite thorough training, adequate sputum specimens
can be obtained in only 50% of CAP. Accordingly, bacte-
ria are identified in less than 30% and 10% of CAP-cases
by sputum and blood culture, respectively [38]. Atypical
pneumonias are rare, i.e., less than 5% based on PCR tech-
niques and probably overestimated in the literature based
on serologic analyses. In addition, apart from severe
legionella infection, exposure to Legionella pneumophilia
often results in seroconversion without disease. Similarly,
in AECOPD positive bacterial sputum cultures are of lim-
ited use, as the majority of AECOPD patients have contin-
uous positive sputum culture due to colonization results.
Importantly, in the PCT group of a previous trial this rate
was similar in patients in whom antibiotic were given or
withheld, as was the outcome [14].
This protocol describes a randomized open multicenter
intervention trial with an expected high external validity.
However, contamination within the proposed open trial
design is obvious. We expect that in a setting where physi-
cians know that they are monitored for antibiotic use, the
antibiotic prescription will be lower as compared to the
real-life setting (Hawthorne effect). Similarly, adherence
to the current guidelines in the guideline group may be
higher as compared to the real-life setting. On the other
hand, physicians may learn from their experience with
PCT testing and change their clinical practice for the treat-
ment of the guideline patients and for example may
reduce antibiotic treatment or treatment duration in
guideline group patients (spill-over effect). The latter bias,
however, will be conservative. Thus, experience gained
from treating patients according to the PCT algorithm in
the intervention arm or other factors attributable to theBMC Health Services Research 2007, 7:102 http://www.biomedcentral.com/1472-6963/7/102
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conduct of the study (for example increased awareness by
physicians because of more conscious decision making)
may affect antibiotic prescription in the guideline arm
and could lead to reduced prescribing or treatment dura-
tion in the control group.
It cannot formally be excluded that these biases could
favour similarity of the two arms and thus be non-con-
servative for the primary non-inferiority comparison.
However, for all secondary endpoints where superiority of
the PCT group is the objective, we believe these biases to
be conservative.
Competing interests
This is an investigator driven study. No commercial spon-
sor had or will have any involvement in design and con-
duct of the studies (i.e., main project and ancillary
projects of the ProHOSP study), namely collection, man-
agement, analysis, and interpretation of the data; and
preparation, decision to submit, review, or approval of the
manuscript.
BM has served as a consultant and received payments
from Brahms to attend meetings; he received research sup-
port and fulfilled speaking engagements. All other con-
tributors and authors have not disclosed any conflicts of
interests.
Authors' contributions
MCC and BM initiated the study, MCC, WZ, HCB, MW,
PS, US, and BM designed the study and wrote the proto-
col. PS, US, RT, CF, IW, SN, CB, RS, CH, TB, CHH, KR, MK,
WZ and BM manage the trial and collect data. PS and MW
performed the statistical analyses. PS, HCB, MW, and BM
drafted the manuscript. All authors amended and com-
mented on the manuscript and approved the final ver-
sion. PS, WZ, MCC, HCB, and BM oversaw the study and
act as guarantor.
Acknowledgements
We are grateful to all local physicians, their staff and patients who partici-
pate in this study. Especially, we thank the staff of the emergency room, 
medical clinics and central laboratories of the University Hospital Basel, the 
local cantonal hospitals Liestal, Aarau, Luzern and Münsterlingen and the 
Bürgerspital Solothurn for their very helpful assistance and technical sup-
port. We thank C. Vincenzi for the help in the planning phase of the study, 
K. Schneider, A. Christ, B. Zehnder, C. Winterhalder, M. Christ and R. 
Fiumefreddo for their help in patient recruitment.
*The ProHOSP study group consisted of the following
Steering Committee: W. Zimmerli, H. C. Bucher, M. Christ-Crain, and 
B. Müller
Data Safety & Monitoring Board: A.P. Perruchoud (Basel), S. Harbarth 
(Geneva), A. Azzola (Lugano)
Endpoint Assessment Committee: R. Bingisser, C. Müller, A. Trampuz
Co-Investigators: U. Schild, K. Regez, M. Kleinknecht
Blinded Outcome Assessment: C. Bähni, S. Meier, P. Spreiter
Statistical Analysis: M. Wolbers, P. Schuetz
Webmaster: F. Dürr
Participating Hospitals
- University Hospital Basel [B. Müller, P. Schuetz, U Schild, M. Wieland]
- Medical University Clinic Liestal [W. Zimmerli, C. Falconnier, C. Brühl-
hardt]
- Medical Clinic Solothurn [R. Schönenberger, R. Thomann, R. Luginbühl]
- Medical Clinic Luzern [V. Briner, C. Henzen, I. Widmer, S. Neidert, B. 
Walz]
- Medical Clinic Aarau [D. Conen, T. Bregenzer, C. Blum, F. Meienberg, A. 
Huber]
- Medical Clinic Münsterlingen [M. Krause, C. Hoess, T. Fricker, M. Zueger]
Funding sources:
This trial is supported in part by a grant from the Swiss National Research 
Foundation (SNF_3200BO-116177/1), contributions from the Foundation 
Basel Institute for Clinical Epidemiology (BICE), the University Hospital 
Basel, the Medical University Clinic Liestal, the Medical Clinic Bürgerspital 
Solothurn, the Swiss Society for Internal Medicine (SGIM), and, mainly, 
from the Department of Endocrinology, Diabetology and Clinical Nutrition, 
University Hospital Basel, Switzerland. Brahms, the manufacturer of the 
PCT assay, provides all assay related material, Kryptor if not already avail-
able on-site, and kits and maintenance required for 10'000 measurements 
related to the study. Additional funding will be sought to complete ancillary 
projects.
References
1. Dixon RE: Economic costs of respiratory tract infections in
the United States.  Am J Med 1985, 78:45-51.
2. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH: Pro-
spective study of aetiology and outcome of adult lower res-
piratory tract infections in the community.  Lancet 1993,
341:511-514.
3. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE,
Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify
low-risk patients with community-acquired pneumonia.  N
Engl J Med 1997, 336:243-250.
4. Aronsky D, Dean NC: How should we make the admission
decision in community-acquired pneumonia?  Med Clin North
Am 2001, 85:1397-1411.
5. Aronsky D, Haug PJ: Assessing the quality of clinical data in a
computer-based record for calculating the pneumonia
severity index.  J Am Med Inform Assoc 2000, 7:55-65.
6. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N,
Town GI, Lewis SA, Macfarlane JT: Defining community acquired
pneumonia severity on presentation to hospital: an interna-
tional derivation and validation study.  Thorax 2003, 58:377-382.
7. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J: Serum pro-
calcitonin and C-reactive protein levels as markers of bacte-
rial infection: a systematic review and meta-analysis.  Clin
Infect Dis 2004, 39:206-217.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2007, 7:102 http://www.biomedcentral.com/1472-6963/7/102
Page 9 of 9
(page number not for citation purposes)
8. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, Nus-
baumer C, Tamm M, Christ-Crain M: Diagnostic and prognostic
accuracy of clinical and laboratory parameters in commu-
nity-acquired pneumonia.  BMC Infect Dis 2007, 7:10.
9. Christ-Crain M, Muller B: Procalcitonin in bacterial infections –
hype, hope, more or less?  Swiss Med Wkly 2005, 135:451-460.
10. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE: Soluble
triggering receptor expressed on myeloid cells and the diag-
nosis of pneumonia.  N Engl J Med 2004, 350:451-458.
11. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR,
Tamm M, Muller B: Effect of procalcitonin-guided treatment on
antibiotic use and outcome in lower respiratory tract infec-
tions: cluster-randomised, single-blinded intervention trial.
Lancet 2004, 363:600-607.
12. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber
PR, Zimmerli W, Harbarth S, Tamm M, Muller B: Procalcitonin
Guidance of Antibiotic Therapy in Community-acquired
Pneumonia: A Randomized Trial.  Am J Respir Crit Care Med 2006,
174:84-93.
13. Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P, Bucher
HC, Muller B: Procalcitonin-guided antibiotic use versus a
standard approach for acute respiratory tract infections in
primary care: study protocol for a randomised controlled
trial and baseline characteristics of participating general
practitioners [ISRCTN73182671].  BMC Fam Pract 2005, 6:34.
14. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C,
Huber P, Muller B, Tamm M: Antibiotic treatment of exacerba-
tions of COPD: a randomized, controlled trial comparing
procalcitonin-guidance  with standard therapy.  Chest 2007,
131:9-19.
15. Bundesamt für Gesundheit (BAG) EDdI: "Kennzahlen der Sch-
weizer Spitäler 2004".  2006 [http://www.bag.admin.ch].
16. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA,
Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie
TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL:
Guidelines for the management of adults with community-
acquired pneumonia. Diagnosis, assessment of severity, anti-
microbial therapy, and prevention.  Am J Respir Crit Care Med
2001, 163:1730-1754.
17. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, Schab-
erg T, Torres A, van der Heijden G, Verheij TJ: Guidelines for the
management of adult lower respiratory tract infections.  Eur
Respir J 2005, 26:1138-1180.
18. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK,
Nelson NA: Antibiotic therapy in exacerbations of chronic
obstructive pulmonary disease.  Ann Intern Med 1987,
106:196-204.
19. Calverley PM, Walker P: Chronic obstructive pulmonary dis-
ease.  Lancet 2003, 362:1053-1061.
20. Gonzales R, Sande MA: Uncomplicated acute bronchitis.  Ann
Intern Med 2000, 133:981-991.
21.  [http://prohosp.easysolution.ch].
22. Greiner W, Claes C, Busschbach JJ, Graf von der Schulenburg JM:
Validating the EQ-5D with time trade off for the German
population.  Eur J Health Econ 2004.
23. Global initiative for chronic obstructive lung disease,
updated 2003   [http://www.goldcopd.com]
24. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D,
Bingisser R, Muller C, Struck J, Muller B, Tamm M: Copeptin, C-
Reactive Protein, and Procalcitonin as Prognostic Biomark-
ers in Acute Exacerbation of COPD.  Chest 2007,
131:1058-1067.
25. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Muller B:
Pro-atrial natriuretic peptide is a prognostic marker in sep-
sis, similar to the APACHE II score: an observational study.
Crit Care 2005, 9:R37-45.
26. Christ-Crain M, Jutla S, Widmer I, Couppis O, Konig C, Pargger H,
Puder J, Edwards R, Muller B, Grossman AB: Measurement of
Serum Free Cortisol Shows Discordant Responsivity to
Stress and Dynamic Evaluation.  J Clin Endocrinol Metab 2007,
92(5):1729-1735.
27. Morgenthaler NG, Mueller B, Struck J, Bergmann A, Redl H, Christ-
Crain M: Copeptin, a stable peptide of the arginine vaso-
pressin precursor, is elevated in hemorrhagic and septic
shock .  Shock 2007.
28. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A,
Muller B: Mid-regional pro-adrenomedullin as a prognostic
marker in sepsis: an observational study.  Crit Care 2005,
9:R816-824.
29. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R,
Harbarth S, Tamm M, Struck J, Bergmann A, Muller B: Pro-
adrenomedullin to predict severity and outcome in commu-
nity-acquired pneumonia [ISRCTN04176397].  Crit Care 2006,
10:R96-103.
30. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement
of midregional proadrenomedullin in plasma with an immu-
noluminometric assay.  Clin Chem 2005, 51:1823-1829.
31. Eto T: A review of the biological properties and clinical impli-
cations of adrenomedullin and proadrenomedullin N-termi-
nal 20 peptide (PAMP), hypotensive and vasodilating
peptides.  Peptides 2001, 22:1693-1711.
32. Ruskoaho H: Cardiac hormones as diagnostic tools in heart
failure.  Endocr Rev 2003, 24:341-356.
33. Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP: B-type natri-
uretic peptide for risk stratification in community-acquired
pneumonia.  J Intern Med 2005, 258:391-393.
34. Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunolumi-
nometric assay for the midregion of pro-atrial natriuretic
Peptide in human plasma.  Clin Chem 2004, 50:234-236.
35. Muller B, Suess E, Schuetz P, Muller C, Bingisser R, Bergmann A, Stolz
D, Tamm M, Morgenthaler NG, Christ-Crain M: Circulating levels
of pro-atrial natriuretic peptide in lower respiratory tract
infections.  J Intern Med 2006, 260:568-576.
36. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the
measurement of copeptin, a stable peptide derived from the
precursor of vasopressin.  Clin Chem 2006, 52:112-119.
37. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R,
Bergmann A, Tamm M, Christ-Crain M: Circulating levels of
copeptin, a novel biomarker, in lower respiratory tract infec-
tions.  Eur J Clin Invest 2007, 37:145-152.
38. Welte T, Suttorp N, Marre R: CAPNETZ-community-acquired
pneumonia competence network.  Infection 2004, 32:234-238.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/7/102/pre
pub